anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background This study investigated the acute effect of post-activation performance enhancement (PAPE) on snatch performance to exhaustion in elite weightlifters.

Methods The study was designed according to a randomized crossover experimental design. Twelve male elite athletes (age; 18.45 ± 0.52 years; height; 1.73 ± 0.03m, body mass; 71.36 ± 11.36kg) voluntarily participated in the study. The participants performed a general warm-up for five minutes, followed by a weightlifting-specific warm-up for five minutes, and rested for two minutes. Then, the athletes performed three different PAPE protocols on different days and performed the snatch performance to exhaustion. Shapiro-Wilk test was applied for the normality test, and the Levene test was applied for the homogeneity test. Repeated measures of two-way analysis of variance (2x3) were applied to analyze the differences between treatments. Greenhouse-Geiser correction test was used for measurements where the sphericity assumption was not met.
The subject of the invention is: provided are a novel phthalocyanine dye for use in photoimmunotherapy, a method for producing the same, and a conjugate of the phthalocyanine dye and an antibody or peptide. According to the present invention, there is provided a compound represented by the following formula (1) or a salt thereof. (wherein X represents a substituent having a hydrophilic group at the end thereof L  3  、L  4  、L  5  And L  6  Each independently represents a divalent linking group. Y represents a group capable of binding to an antibody or a peptide. R  3  Represents an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogen atom or a-SR  11  、‑SOR  12  Aryl group having 6 to 10 carbon atoms, -N (R)  13  )(R  14  ) or-NO  2  And the like. In the presence of a plurality of R  3  In the case of (2), they may be the same or different. S represents an integer of 0 to 4. )
Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.
BACKGROUND AND OBJECTIVE: Sepsis is a life-threatening disease with high mortality, incidence, and morbidity. Corticosteroids (CS) are a recommended treatment for sepsis, but some patients respond negatively to CS therapy. Early prediction of corticosteroid responsiveness can help intervene and reduce mortality. In this study, we aim to develop a data mining methodology for predicting CS responsiveness of septic patients.
METHODS: We used data from a randomized controlled trial called APROCCHSS, which recruited 1241 septis patients to study the effectiveness of corticotherapy. We conducted a thorough study of multiple machine learning models to select the most efficient prediction model, called "signature". We evaluated the performance of the signature using precision, sensitivity, and specificity values.
RESULTS: We found that Logistic Regression was the best model with an AUC of 72%. We conducted further experiments to examine the impact of additional features and the model's generalizability to different groups of patients. We also performed a statistical analysis to analyze the effect of the treatment at the individual level and on the population as a whole.
CONCLUSIONS: Our data mining methodology can accurately predict cortico-sensitivity or resistance in septis patients. The signature has been deployed into the Assistance Publique - Hôpitaux de Paris (APHP) information system as a web service, taking patient information as input and providing a prediction of cortico-sensitivity or resistance. Early prediction of corticosteroid responsiveness can help clinicians intervene promptly and improve patient outcomes.
BACKGROUND: Human Assumed Central Sensitization (HACS) is involved in the development and maintenance of chronic low back pain (CLBP). The Central Sensitization Inventory (CSI) was developed to evaluate the presence of HACS, with a cut-off value of 40/100. However, various factors including pain conditions (e.g., CLBP), contexts, and gender may influence this cut-off value. Unsupervised clustering approaches can address these complexities by considering diverse factors and exploring possible HACS-related subgroups. Therefore, this study aimed to determine the cut-off values for a Dutch-speaking population with CLBP based on unsupervised machine learning.
METHODS: Questionnaire data covering pain, physical, and psychological aspects were collected from patients with CLBP and aged-matched healthy controls (HC). Four clustering approaches were applied to identify HACS-related subgroups based on the questionnaire data and gender. The clustering performance was assessed using internal and external indicators. Subsequently, receiver operating characteristic (ROC) analysis was conducted on the best clustering results to determine the optimal cut-off values.
RESULTS: The study included 63 HCs and 88 patients with CLBP. Hierarchical clustering yielded the best results, identifying three clusters: healthy group, CLBP with low HACS level, and CLBP with high HACS level groups. The cut-off value for the overall groups were 35 (sensitivity 0.76, specificity 0.76).
CONCLUSION: This study found distinct patient subgroups. An overall CSI cut-off value of 35 was suggested. This study may provide new insights into identifying HACS-related patterns and contributes to establishing accurate cut-off values.
1,136,130. Thermosealable films. MONTECATINI SOCIETA GENERALE PER L'INDUSTRIA MINERARIA E CHIMICA. 21 April, 1966 [27 April, 1965], No. 17487/66. Heading B2E. A thermosealable film for packing comprises an olefin polymeric film coated with a primer which is the reaction product of an amine with an oxyranic derivative in a molar ratio of from 1:0.01 to 1:0.99 respectively and a further layer of an acrylonitrile, vinylidene chloride, vinyl chloride, or vinyl acetate copolymer. The primer layer may consist of a reaction product of an oxyranic derivative with an alkyleneimine polymer or with a simple amino-compound such as ethylene diamine, diethylene triamine or tetra-ethylene pentamine. The oxyranic compound may be a polymeric reaction product of epichlorohydrin with a bis-phenol or with a glycidyl derivative such as a diglycidyl ether of diethylene glycol or N,N'-diglycidyl piperazine. The substrate may be polypropylene film which has been previously bistretched. It may have been treated electrically and the film may be unstretched or stretched in only one direction. The primer layer may be coated on one or both sides of the film. Stretching may be carried out after coating. The primer may be applied as an emulsion or dispersion in water or in an organic solvent by spreading or by immersion at the film.
PROBLEM TO BE SOLVED: To obtain a medium capable of not causing the crisis of prostatic hyperplasia in male mammals, controlling bone resorption and bone metabolic turnover, preventing bone loss, keeping bone strength and reducing serum cholesterol by making the medicine include a specific compound. SOLUTION: This medicine contains an effective amount of a compound of formula I (G is a group of formula II, a group of formula III or the like; E and B are CH or N; R4 is H, OH, F or the like). Preferably the compound of formula I is cis-6-(4-fluoro-phenyl)-5-[4-(2-pxperidin-1-yl-ethoxy)-phenyl]-5,6,7,8- tetrahydro-naphthalen-2-ol, etc. Preferably the dose of the compound is 0.25-25 mg/day and the compound is orally administered. The composition is administered as a medicine composition. The composition can be used as a tablet, chewable tablet, capsule, solution, parenteral solution, troche, etc.
BACKGROUND: The role of patients in healthcare research is slowly evolving, although patient roles in the research process are limited. This paper reports on a patient-led research project aiming to develop a musical hearing training programme for patients with a cochlear implant (CI): the Musi-CI programme. A CI is an inner ear prosthesis that allows people with severe hearing loss to hear. However, while speech can be understood, CI users cannot fully enjoy music or feel aversion to it. The Musi-CI programme aims to reduce this music aversion to ultimately improve music enjoyment and social participation. The development of the Musi-CI programme was supported by a consortium of professionals in CI rehabilitation and research. The aim of this paper is to describe and evaluate the Musi-CI programme development process and its impact on professional CI rehabilitation and research.
METHODS: Programme development was described using a 3-layered process model of action research, distinguishing the CI user process, the healthcare professional process and the research process. To evaluate perceptions on the programme development process, consortium partners provided written comments and participated in a reflexive evaluation session that was video-recorded. Reflexive evaluation aims for collective learning and strengthening collaboration among participants. Written comments and video data were analysed using template analysis.
RESULTS: The involvement of an expert by experience was perceived as challenging but rewarding for all consortium partners, opening up new perspectives on CI-rehabilitation practice and research. Data analysis revealed two themes on the programme development process, professional space and acknowledgement, and two themes on the outcomes on CI rehabilitation and research: critical reflection and paradigm shift.
CONCLUSION: Experts by experience represent a different knowledge domain that may contribute to change in rehabilitation and research.
PATIENT OR PUBLIC CONTRIBUTION: The development of the programme was initiated by a professional musician and CI user who organized the funding, had a leading role throughout the research process, including the write-up of the results, and co-authored this paper.
The efficacy of ZURZUVAE for the treatment of postpartum depression (PPD) in adults was demonstrated in two randomized, placebo-controlled, double-blind, multicenter studies (Study 1, NCT04442503 and Study 2, NCT02978326) in women with PPD who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode (DSM-5) with onset of symptoms in the third trimester or within 4 weeks of delivery. In these studies, concomitant use of existing oral antidepressants was allowed for patients taking a stable dose of oral antidepressant for at least 30 days before baseline. These studies included patients with HAMD-17 scores ≥ 26 at baseline. 

In Study 1, patients received 50 mg of ZURZUVAE (N=98) or placebo (N=97) once daily in the evening with fat-containing food for 14 days, with the option to reduce the dosage based on tolerability to 40 mg once daily of ZURZUVAE or placebo. The patients were followed for a minimum of 4 weeks after the 14-day treatment course. 

In Study 2, patients received another zuranolone capsule formulation (approximately equivalent to 40 mg of ZURZUVAE) (N=76) or placebo (N=74) once daily in the evening with food for 14 days. The patients were followed for a minimum of 4 weeks after the 14-day treatment course. 

Baseline Demographics and Disease Characteristics

In Studies 1 and 2, the baseline demographic and disease characteristics of patients were similar between the ZURZUVAE and placebo groups. In Study 1, patients had a mean age of 30 years (range 19 to 44 years); were 70% White, 22% Black or African American, 1% Asian, and 7% were other races; and 38% were of Hispanic or Latino ethnicity. Baseline use of stable oral antidepressants was reported in 15% of patients. In Study 2, patients had a mean age of 28 years (range 18 to 44 years); were 56% White, 41% Black or African American, 1% Asian, and 2% were other races; and 23% were of Hispanic or Latino ethnicity. Baseline use of stable oral antidepressants was reported in 19% of patients. 

The primary endpoint for Studies 1 and 2 was the change from baseline in depressive symptoms as measured by the HAMD-17 total score at Day 15. In these studies, patients in the ZURZUVAE groups experienced statistically significantly greater improvement on the primary endpoint compared to patients in the placebo groups, as shown in Table 5. For Study 1, the key secondary endpoints included change from baseline in HAMD-17 total score at Days 3, 28, and 45. 

Subgroup analyses of the primary endpoint did not suggest differences in response to 50 mg of ZURZUVAE for age, race, or BMI. 

The time course of response for 50 mg ZURZUVAE compared to placebo for Study 1 is shown in Figure 3. 

Figure 3 Mean Change from Baseline in HAM-D Total Score Over Time (Days) in Women with PPD in Study 1

*Both phases were double-blind.
The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to establish a habitat imaging framework for assessing regional heterogeneity within individual tumors. This framework identifies three PET/CT subtypes, which maintain prognostic value after adjusting for clinicopathologic risk factors including tumor volume. Additionally, these subtypes complement ctDNA in predicting disease recurrence. Radiogenomics analysis unveil the molecular underpinnings of these imaging subtypes, highlighting downregulation in interferon alpha and gamma pathways in the high-risk subtype. In summary, our study demonstrates that these habitat imaging subtypes effectively stratify NSCLC patients based on their risk levels for disease recurrence after initial curative surgery or radiotherapy, providing valuable insights for personalized treatment approaches.
Anxiety-related attentional bias (AB) is the preferential processing of threat observed in clinical and sub-clinical anxiety. Attention bias modification training (ABMT) is a computerized cognitive training technique designed to systematically direct attention away from threat and ameliorate AB, but mixed and null findings have highlighted gaps in our understanding of mechanisms underlying ABMT and how to design the most effective delivery systems. One neuromodulation technique, transcranial direct current stimulation (tDCS) across the prefrontal cortex (PFC) may augment the effects of ABMT by strengthening top-down cognitive control processes, but the evidence base is limited and has not been generalized to current approaches in digital therapeutics, such as mobile applications. The present study tested whether tDCS across the PFC, versus sham stimulation, effectively augments the beneficial effects of a gamified ABMT mobile app. Thirty-eight adults (Mage = 23.92, SD = 4.75; 18 females) evidencing low-to-moderate anxiety symptoms were randomly assigned to active or sham tDCS for 30-minutes while receiving ABMT via a mobile app. Participants reported on potential moderators of ABMT, including life stress and trait anxiety. ECG was recorded during a subsequent stressor to generate respiratory sinus arrhythmia (RSA) suppression as a metric of stress resilience.
Individuals who apply to the urology service for TURP or TURM will be informed about the study 1 day before the surgery, and the questions in the patient introduction form will be asked to the patients who declared that they agreed to participate in the study in written and verbal form. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality, and the Patient follow-up form will be applied to determine the confounding factors that may affect the sleep. The patient's feet will be kept in the footbath device for ten minutes. After the foot bath, the patient's feet will be completely dried with a towel and the existing socks and anti-embolic socks will be put on again. On the morning of the 1st postoperative day, the patient will be asked the questions in the RCSQ and the follow-up form, and the data collection process of the study will be terminated.
Plasmacytoma is a rare plasma cell dyscrasia that grows in bones or soft tissues such as the pharynx. Soft tissue plasmacytomas are rare, and a higher burden has been reported in the upper aero-digestive tract, often manifesting as hoarseness, dysphagia, or odynophagia. Due to their rarity, extramedullary plasmacytomas (EMPs) have unknown prognostic factors, and guidelines for optimal management are still lacking. However, radiation therapy and surgery have been used with positive outcomes. Herein, we describe a unique case of plasmacytoma of the pharyngeal tissue in a male patient with a history of HIV disease. The patient completed 28 sessions of radiation therapy, resulting in an improvement in his throat pain and hoarseness. Given the patient's age and lack of traditional risk factors for head and neck cancers, his hoarseness and odynophagia proved to be a diagnostic conundrum. Although infrequent, soft tissue plasmacytomas should be considered in the differential diagnosis of head and neck tumors.
Participants in the Wait List condition will receive no treatment for approximately 8 weeks, and they will be asked to complete pre-wait list, post-wait list and 3-month follow-up assessments. After all assessments have been completed, this group will be offered the same 8 individual, 1-hour, weekly sessions of SMART (no further assessments needed).
SIGNIFICANCE: Hyperspectral dark-field microscopy (HSDFM) and data cube analysis algorithms demonstrate successful detection and classification of various tissue types, including carcinoma regions in human post-lumpectomy breast tissues excised during breast-conserving surgeries.
AIM: We expand the application of HSDFM to the classification of tissue types and tumor subtypes in pre-histopathology human breast lumpectomy samples.
APPROACH: Breast tissues excised during breast-conserving surgeries were imaged by the HSDFM and analyzed. The performance of the HSDFM is evaluated by comparing the backscattering intensity spectra of polystyrene microbead solutions with the Monte Carlo simulation of the experimental data. For classification algorithms, two analysis approaches, a supervised technique based on the spectral angle mapper (SAM) algorithm and an unsupervised technique based on the K-means algorithm are applied to classify various tissue types including carcinoma subtypes. In the supervised technique, the SAM algorithm with manually extracted endmembers guided by H&E annotations is used as reference spectra, allowing for segmentation maps with classified tissue types including carcinoma subtypes.
RESULTS: The manually extracted endmembers of known tissue types and their corresponding threshold spectral correlation angles for classification make a good reference library that validates endmembers computed by the unsupervised K-means algorithm. The unsupervised K-means algorithm, with no a priori information, produces abundance maps with dominant endmembers of various tissue types, including carcinoma subtypes of invasive ductal carcinoma and invasive mucinous carcinoma. The two carcinomas' unique endmembers produced by the two methods agree with each other within <2% residual error margin.
CONCLUSIONS: Our report demonstrates a robust procedure for the validation of an unsupervised algorithm with the essential set of parameters based on the ground truth, histopathological information. We have demonstrated that a trained library of the histopathology-guided endmembers and associated threshold spectral correlation angles computed against well-defined reference data cubes serve such parameters. Two classification algorithms, supervised and unsupervised algorithms, are employed to identify regions with carcinoma subtypes of invasive ductal carcinoma and invasive mucinous carcinoma present in the tissues. The two carcinomas' unique endmembers used by the two methods agree to <2% residual error margin. This library of high quality and collected under an environment with no ambient background may be instrumental to develop or validate more advanced unsupervised data cube analysis algorithms, such as effective neural networks for efficient subtype classification.
PURPOSE:To obtain a tape preparation for transcutaneous administration, causing extremely little loss of drug component and having excellent processability, dimension stability and shape stability, by applying a releasing liner made of a particular glassine paper to a tacky adhesive layer containing a nitrous acid-based coronary vasodilator. CONSTITUTION:A tacky adhesive layer containing a nitrous acid-based coronary vasodilator (e.g. amyl nitrite, nitroglycerol, triethanolamine trinitrate, etc.) is formed on a substrate (e.g. sheet or film of polyester, polyamide, etc.) impermeable of said drug. A releasing liner obtained by releasing treatment of a surface of a laminate composed of a glassine paper (preferably having a thickness of 40-100mum) and containing >=0.5wt.%, preferably 0.5-5wt.% PVA is applied to the surface of the tacky adhesive layer to obtain the objective tape preparation. Preferably, a water-vapor impermeable material (e.g. PE) is used as another constituent layer of the releasing liner.
PURPOSE OF REVIEW: There is a long history of implantation of absorbable and nonabsorbable materials to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP). The focus of this review is to review the development of new materials for use in the surgical management of both pelvic conditions following an unacceptable level of severe complications in the use of polypropylene mesh (PPM). We discuss current concepts relating to the development of new materials with particular reference to our experience with polyurethane mesh.
RECENT FINDINGS: Our review highlights the strategies that manufacturers and researchers are employing to improve PPM using collagen gels and stem cells, or to find alternatives. We conclude that current preclinical safety testing is inadequate, and the field requires better in vivo testing. Specifically, we highlight novel techniques demonstrating the degradation of polypropylene potentially elucidating the link between PPM degradation and induction of inflammation leading to adverse side effects.
SUMMARY: This field badly needs innovation in developing new materials and in testing these to ensure materials will benefit patients. A collaboration between materials scientists and clinicians is needed to facilitate the translation of basic research and preclinical testing into patient benefit for the treatment of SUI and POP.
The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.